CSTL
Castle Biosciences, Inc.
CSTL has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over CSTL overall, supported by stronger fundamentals and stronger modeled upside.
CSTL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
CSTL's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CSTL PE Valuation
CSTL has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CSTL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CSTL's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CSTL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.75 | -$0.30 |
| Q2 2026 | -$0.64 | -$0.29 |
| Q1 2026 | -$0.42 | -$0.23 |
| Q4 2025 | -$0.83 | -234% |
| Q3 2025 | -$0.45 | -305% |
| Q2 2025 | -$0.35 | -$0.23 |
| Q1 2025 | -$0.19 | +$0.94 |
| Q4 2024 | $0.62 | +$2.76 |
CSTL is still losing money, but far less than before: $0.75 per share over the past year, against $3.35 at its worst in mid-2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CSTL on earnings quality, reporting a profit while its opponent remains loss making.
CSTL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $102.9M | +24% |
| Q2 2026 | $103.5M | +20% |
| Q1 2026 | $83.7M | -4.9% |
| Q4 2025 | $87M | +0.8% |
| Q3 2025 | $83M | -3.2% |
| Q2 2025 | $86.2M | -0.9% |
| Q1 2025 | $88M | +21% |
| Q4 2024 | $86.3M | +31% |
CSTL's revenue is growing: $103M last quarter, up 24% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.6% | +5.5 points |
| Q2 2026 | -3% | +2 points |
| Q1 2026 | -22% | +9.7 points |
| Q4 2025 | -4.4% | -9.1 points |
| Q3 2025 | -8.2% | -14 points |
| Q2 2025 | -4.9% | -11 points |
| Q1 2025 | -32% | -24 points |
| Q4 2024 | 4.7% | +13 points |
CSTL's operating margin was −2.6% last quarter, up 5.5 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CSTL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CSTL on profitability, with a higher operating margin.
CSTL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12.2M | +57% |
| Q2 2026 | $6.6M | -43% |
| Q1 2026 | -$34.6M | -$23.8M |
| Q4 2025 | $19.7M | +18% |
| Q3 2025 | $7.8M | -54% |
| Q2 2025 | $11.6M | -38% |
| Q1 2025 | -$10.8M | +$5.2M |
| Q4 2024 | $16.8M | +14% |
CSTL still generates free cash flow, though less than at its 2025 peak: $4M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CSTL on cash flow, with more consistent year-over-year improvement.
CSTL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +234K shares |
| 1 year | +5.4% | +1.6M shares |
| 3 years | +14% | +3.8M shares |
| 5 years | +21% | +5.3M shares |
| Available history | +64% | +11.9M shares |
CSTL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CSTL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -9.6x | Net Cash |
| Q2 2025 | -3.7x | Net Cash |
| Q1 2025 | -2.8x | Net Cash |
| Q4 2024 | -4.5x | Net Cash |
| Q3 2024 | -6.8x | Net Cash |
| Q2 2020 | -19.8x | Net Cash |
| Q1 2020 | -8.1x | Net Cash |
| Q4 2019 | -9.6x | Net Cash |
CSTL has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CSTL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.0 | Neutral |
| Stochastic | 63.5 | Neutral |
CSTL's weekly RSI is 57 (neutral) and its Stochastic is 63 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CSTL PE vs Healthcare Sector
| Metric | CSTL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CSTL has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CSTL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.4 | 0.3% above |
| 20 week MA | $31.5 | 9.6% above |
| 50 week MA | $30.0 | 15% above |
| 100 week MA | $26.4 | 31% above |
| 200 week MA | $24.4 | 41% above |
CSTL is in an uptrend: it's above all five of its weekly moving averages, and 41% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
CSTL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $34.0 | $71.3 | +110% |
| 2021 | $71.3 | $42.6 | -40% |
| 2022 | $42.6 | $23.2 | -45% |
| 2023 | $23.2 | $21.6 | -7.1% |
| 2024 | $21.6 | $26.8 | +24% |
| 2025 | $26.8 | $39.4 | +47% |
| 2026 YTD | $39.4 | $34.5 | -12% |
CSTL's yearly returns have swung widely, from +110% in 2020 to −45% in 2022. It's down 12% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CSTL on returns for 2026, with the stronger performance.